WO2009124312A3 - Consensus sequences of chikungunya viral proteins, nucleic acid molecules encoding the same, and compositions and methods for using the same - Google Patents

Consensus sequences of chikungunya viral proteins, nucleic acid molecules encoding the same, and compositions and methods for using the same Download PDF

Info

Publication number
WO2009124312A3
WO2009124312A3 PCT/US2009/039656 US2009039656W WO2009124312A3 WO 2009124312 A3 WO2009124312 A3 WO 2009124312A3 US 2009039656 W US2009039656 W US 2009039656W WO 2009124312 A3 WO2009124312 A3 WO 2009124312A3
Authority
WO
WIPO (PCT)
Prior art keywords
same
consensus
chikv
nucleic acid
acid molecules
Prior art date
Application number
PCT/US2009/039656
Other languages
French (fr)
Other versions
WO2009124312A2 (en
Inventor
David B. Weiner
Karuppiah Muthumani
Original Assignee
The Trustees Of The University Of Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Trustees Of The University Of Pennsylvania filed Critical The Trustees Of The University Of Pennsylvania
Priority to ES09727698.4T priority Critical patent/ES2588738T3/en
Priority to EP09727698.4A priority patent/EP2274442B1/en
Priority to US12/936,186 priority patent/US8852609B2/en
Priority to JP2011503242A priority patent/JP5744719B2/en
Priority to CN2009801128936A priority patent/CN101990580A/en
Priority to CA2720166A priority patent/CA2720166A1/en
Priority to AU2009231559A priority patent/AU2009231559B2/en
Publication of WO2009124312A2 publication Critical patent/WO2009124312A2/en
Publication of WO2009124312A3 publication Critical patent/WO2009124312A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Consensus CHIKV El protein, consensus CHIKV E2 protein, consensus CHIKV capsid protein, or fragments and homologues thereof, and nucleic acid molecules that encode the same are disclosed. A consensus CHIKV Env protein which includes CHIKV El consensus protein, CHIKV E2 consensus protein, CHIKV E3 consensus protein, or fragments and homologues thereof and nucleic acid molecules that encode the same are also disclosed. Compositions and recombinant vaccines comprising CHIKV consensus proteins, and methods of using them are disclosed.
PCT/US2009/039656 2008-04-04 2009-04-06 Consensus sequences of chikungunya viral proteins, nucleic acid molecules encoding the same, and compositions and methods for using the same WO2009124312A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
ES09727698.4T ES2588738T3 (en) 2008-04-04 2009-04-06 Consensus sequences of Chikungunya virus proteins, nucleic acid molecules that encode them, and compositions and methods of use thereof
EP09727698.4A EP2274442B1 (en) 2008-04-04 2009-04-06 Consensus sequences of chikungunya viral proteins, nucleic acid molecules encoding the same, and compositions and methods for using the same
US12/936,186 US8852609B2 (en) 2008-04-04 2009-04-06 Consensus sequences of chikungunya viral proteins, nucleic acid molecules encoding the same, and compositions and methods for using the same
JP2011503242A JP5744719B2 (en) 2008-04-04 2009-04-06 Chikungunya virus protein consensus sequence, nucleic acid molecule encoding the same, and compositions and methods using the same
CN2009801128936A CN101990580A (en) 2008-04-04 2009-04-06 Consensus sequences of chikungunya viral proteins, nucleic acid molecules encoding the same, and compositions and methods for using the same
CA2720166A CA2720166A1 (en) 2008-04-04 2009-04-06 Consensus sequences of chikungunya viral proteins, nucleic acid molecules encoding the same, and compositions and methods for using the same
AU2009231559A AU2009231559B2 (en) 2008-04-04 2009-04-06 Consensus sequences of Chikungunya viral proteins, nucleic acid molecules encoding the same, and compositions and methods for using the same

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4266108P 2008-04-04 2008-04-04
US61/042,661 2008-04-04

Publications (2)

Publication Number Publication Date
WO2009124312A2 WO2009124312A2 (en) 2009-10-08
WO2009124312A3 true WO2009124312A3 (en) 2010-01-14

Family

ID=41136129

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/039656 WO2009124312A2 (en) 2008-04-04 2009-04-06 Consensus sequences of chikungunya viral proteins, nucleic acid molecules encoding the same, and compositions and methods for using the same

Country Status (9)

Country Link
US (1) US8852609B2 (en)
EP (1) EP2274442B1 (en)
JP (2) JP5744719B2 (en)
KR (1) KR101589511B1 (en)
CN (2) CN101990580A (en)
AU (1) AU2009231559B2 (en)
CA (1) CA2720166A1 (en)
ES (1) ES2588738T3 (en)
WO (1) WO2009124312A2 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010071610A1 (en) * 2008-12-19 2010-06-24 Agency For Science, Technology And Research (A*Star) Severe chikungunya biomarkers
EP2374816B1 (en) * 2010-04-07 2016-09-28 Agency For Science, Technology And Research Binding molecules against Chikungunya virus and uses thereof
WO2011124635A1 (en) 2010-04-07 2011-10-13 Humalys Binding molecules against chikungunya virus and uses thereof
BR112013011705B1 (en) 2010-11-12 2022-04-05 The Trustees Of The University Of Pennsylvania Consensus prostate antigens, nucleic acid molecule encoding the same, and vaccine and uses comprising the same
US20140050754A1 (en) * 2010-12-10 2014-02-20 National Healthcare Group Pte Ltd Immunogenic chikungunya virus peptides
EA037377B1 (en) * 2011-02-11 2021-03-22 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Vaccine for inducing an immune response against hbv
JP6567824B2 (en) * 2011-10-12 2019-08-28 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア Human papillomavirus vaccine and method of use thereof
EP2712871A1 (en) * 2012-09-27 2014-04-02 Institut Pasteur Recombinant Measles virus expressing Chikungunya virus polypeptides and their applications
MX2015007575A (en) 2012-12-13 2016-03-15 Univ Pennsylvania Dna antibody constructs and method of using same.
CN114181961A (en) 2013-03-12 2022-03-15 宾夕法尼亚大学理事会 Improved vaccines for human papilloma virus and methods of use thereof
CN105050616A (en) * 2013-03-15 2015-11-11 宾夕法尼亚大学理事会 Compositions comprising hypoxia inducible factor-1 alpha and methods of using the same
EP3021868A4 (en) * 2013-07-19 2017-03-01 Integral Molecular, Inc. Antibodies against chikungunya virus and uses thereof
JP7268958B2 (en) 2014-12-01 2023-05-08 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア DNA antibody constructs and methods of use thereof
KR20180138204A (en) * 2016-03-21 2018-12-28 데이비드 비. 웨이너 DNA antibody constructs and methods for their use
JP6795468B2 (en) * 2017-07-14 2020-12-02 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア Human papillomavirus vaccine and how to use it
WO2019148086A1 (en) * 2018-01-26 2019-08-01 The Wistar Institute Of Anatomy And Biology Vaccines against mosquito-borne viruses, and methods of using same
CN109536464B (en) * 2018-12-10 2022-06-10 中国科学院武汉病毒研究所 Chikungunya virus infectious clone with deletion of capsid protein gene, construction method and application in preparation of attenuated vaccine
KR102202082B1 (en) 2019-09-25 2021-01-11 충북대학교 산학협력단 Monoclonal antibody with specificity for the envelope protein domain Ⅱ of chikungunya virus, hybridoma cell line producing the same and use thereof
JP7075130B2 (en) * 2019-10-25 2022-05-25 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア Human papillomavirus vaccine and how to use it

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050053620A1 (en) * 2001-11-20 2005-03-10 Mitsuo Honda Recombinant vaccinia virus vaccine
US7078218B2 (en) * 2002-12-13 2006-07-18 Alphavax, Inc. Alphavirus particles and methods for preparation
WO2007105111A2 (en) * 2006-03-15 2007-09-20 Institut Pasteur Novel isolated and purified strains of chikungunya virus and polynucleotides and polypeptides sequences, diagnostic and immunogenical uses thereof

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5077044A (en) * 1980-05-19 1991-12-31 The Board Of Trustees Of The Leland Stanford Jr. University Novel non-reverting shigella live vaccines
US5338683A (en) * 1981-12-24 1994-08-16 Health Research Incorporated Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
US5110587A (en) * 1981-12-24 1992-05-05 Health Research, Incorporated Immunogenic composition comprising synthetically modified vaccinia virus
US4722848A (en) * 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US5174993A (en) * 1981-12-24 1992-12-29 Health Research Inc. Recombinant avipox virus and immunological use thereof
US5036006A (en) * 1984-11-13 1991-07-30 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US4945050A (en) * 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
GB8508845D0 (en) * 1985-04-04 1985-05-09 Hoffmann La Roche Vaccinia dna
US5223424A (en) * 1985-09-06 1993-06-29 Prutech Research And Development Attenuated herpesviruses and herpesviruses which include foreign DNA encoding an amino acid sequence
US5310668A (en) * 1986-06-20 1994-05-10 Merck & Co., Inc. Varicella-zoster virus as a live recombinant vaccine
US5242829A (en) * 1986-09-23 1993-09-07 Therion Biologics Corporation Recombinant pseudorabies virus
US5294441A (en) * 1987-06-04 1994-03-15 Washington University Avirulent microbes and uses therefor: salmonella typhi
US5387744A (en) * 1987-06-04 1995-02-07 Washington University Avirulent microbes and uses therefor: Salmonella typhi
IL86583A0 (en) * 1987-06-04 1988-11-15 Molecular Eng Ass Vaccine containing a derivative of a microbe and method for the production thereof
US5112749A (en) * 1987-10-02 1992-05-12 Praxis Biologics, Inc. Vaccines for the malaria circumsporozoite protein
US5225336A (en) * 1989-03-08 1993-07-06 Health Research Incorporated Recombinant poxvirus host range selection system
CH682669A5 (en) * 1989-03-08 1993-10-29 Health Research Inc recombinant virus engineered to express a gene product in a host, corresponding methods and vaccine.
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
ATE138784T1 (en) * 1989-03-31 1996-06-15 Univ Washington AVIRULENT PHOP-TYPE MICROORGANISMS CONTAINING VACCINES
EP0431668B1 (en) * 1989-12-04 1995-02-15 Akzo Nobel N.V. Recombinant herpesvirus of turkeys and live vector vaccines derived thereof
US5294548A (en) * 1990-04-02 1994-03-15 American Biogenetic Sciences, Inc Recombianant Hepatitis a virus
US5462734A (en) * 1990-11-02 1995-10-31 Wisconsin Alumni Research Foundation Bovine herpesvirus vaccine and method of using same
US5240703A (en) * 1991-03-01 1993-08-31 Syntro Corporation Attenuated, genetically-engineered pseudorabies virus s-prv-155 and uses thereof
US5273525A (en) * 1992-08-13 1993-12-28 Btx Inc. Injection and electroporation apparatus for drug and gene delivery
US5981505A (en) * 1993-01-26 1999-11-09 The Trustees Of The University Of Pennsylvania Compositions and methods for delivery of genetic material
US5593972A (en) * 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
US5993434A (en) * 1993-04-01 1999-11-30 Genetronics, Inc. Method of treatment using electroporation mediated delivery of drugs and genes
US5702359A (en) * 1995-06-06 1997-12-30 Genetronics, Inc. Needle electrodes for mediated delivery of drugs and genes
US5439440A (en) * 1993-04-01 1995-08-08 Genetronics, Inc. Electroporation system with voltage control feedback for clinical applications
US5739118A (en) * 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
NL9401820A (en) * 1994-11-02 1996-06-03 Meyn Maschf Device for processing poultry suspended from its legs.
US5962428A (en) * 1995-03-30 1999-10-05 Apollon, Inc. Compositions and methods for delivery of genetic material
US5810762A (en) * 1995-04-10 1998-09-22 Genetronics, Inc. Electroporation system with voltage control feedback for clinical applications
US6261281B1 (en) * 1997-04-03 2001-07-17 Electrofect As Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells
DK1023107T3 (en) * 1997-04-03 2006-12-27 Electrofect As Method of administration of pharmaceutical compositions and nucleic acids in skeletal muscle
US6055453A (en) * 1997-08-01 2000-04-25 Genetronics, Inc. Apparatus for addressing needle array electrodes for electroporation therapy
US6241701B1 (en) * 1997-08-01 2001-06-05 Genetronics, Inc. Apparatus for electroporation mediated delivery of drugs and genes
US6216034B1 (en) * 1997-08-01 2001-04-10 Genetronics, Inc. Method of programming an array of needle electrodes for electroporation therapy of tissue
US6135990A (en) * 1997-12-17 2000-10-24 University Of South Florida Electroporation device and method
US6778853B1 (en) * 1997-12-17 2004-08-17 University Of South Florida Electroporation device
US6120493A (en) * 1998-01-27 2000-09-19 Genetronics, Inc. Method for the introduction of therapeutic agents utilizing an electroporation apparatus
EP1079890A4 (en) * 1998-05-08 2008-12-03 Genetronics Inc Electrically induced vessel vasodilation
US6678556B1 (en) * 1998-07-13 2004-01-13 Genetronics, Inc. Electrical field therapy with reduced histopathological change in muscle
EP1100579B1 (en) * 1998-07-13 2015-09-02 Inovio Pharmaceuticals, Inc. Skin and muscle-targeted gene therapy by pulsed electrical field
AU2002211524B2 (en) * 2000-10-04 2007-03-22 The Trustees Of The University Of Pennsylvania Highly expressible genes
US8209006B2 (en) * 2002-03-07 2012-06-26 Vgx Pharmaceuticals, Inc. Constant current electroporation device and methods of use
US7245963B2 (en) * 2002-03-07 2007-07-17 Advisys, Inc. Electrode assembly for constant-current electroporation and use
NZ570709A (en) * 2003-06-13 2010-04-30 Univ Pennsylvania Nucleic acid sequences encoding and compositions comprising IgE signal peptide and/or IL-15 and methods for using the same
ATE535249T1 (en) * 2003-06-13 2011-12-15 Univ Pennsylvania VACCINES, IMMUNOTHERAPEUTICS AND METHODS FOR USE THEREOF
US8865184B2 (en) * 2006-09-01 2014-10-21 Bharat Biotech International Limited Vaccine for chikungunya virus infection
CN105457157B (en) * 2006-10-17 2020-04-14 因诺维奥制药公司 Electroporation device and method for mammalian cell electroporation using the same
US9353353B2 (en) * 2008-11-26 2016-05-31 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Virus-like particles (VLPs) prepared from chikungunya virus structural proteins

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050053620A1 (en) * 2001-11-20 2005-03-10 Mitsuo Honda Recombinant vaccinia virus vaccine
US7078218B2 (en) * 2002-12-13 2006-07-18 Alphavax, Inc. Alphavirus particles and methods for preparation
WO2007105111A2 (en) * 2006-03-15 2007-09-20 Institut Pasteur Novel isolated and purified strains of chikungunya virus and polynucleotides and polypeptides sequences, diagnostic and immunogenical uses thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
EDELMAN ET AL.: "Phase II safety and immunogenicity study of live chikungunya virus vaccine TSI-GSD-218.", AM. J. TROP. MED. HYG., vol. 62, no. 6, June 2000 (2000-06-01), pages 681 - 685, XP002487087 *
KUMAR ET AL.: "Molecular characterization of chikungunya virus from Andhra Pradesh, India & phylogenetic relationship with Central African isolates.", IND. J. MED. RES., vol. 126, no. 6, December 2007 (2007-12-01), pages 534 - 540, XP008133197 *
See also references of EP2274442A4 *

Also Published As

Publication number Publication date
EP2274442A4 (en) 2011-10-05
JP2011516070A (en) 2011-05-26
AU2009231559A2 (en) 2012-07-12
EP2274442A2 (en) 2011-01-19
ES2588738T3 (en) 2016-11-04
JP5744719B2 (en) 2015-07-08
WO2009124312A2 (en) 2009-10-08
CN101990580A (en) 2011-03-23
AU2009231559A1 (en) 2009-10-08
EP2274442B1 (en) 2016-06-29
AU2009231559B2 (en) 2015-10-22
KR20100135879A (en) 2010-12-27
JP2015083017A (en) 2015-04-30
US8852609B2 (en) 2014-10-07
CN107083391A (en) 2017-08-22
KR101589511B1 (en) 2016-02-01
CA2720166A1 (en) 2009-10-08
US20110104198A1 (en) 2011-05-05

Similar Documents

Publication Publication Date Title
WO2009124312A3 (en) Consensus sequences of chikungunya viral proteins, nucleic acid molecules encoding the same, and compositions and methods for using the same
WO2009147248A3 (en) Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases
WO2010138263A3 (en) Novel aav 's and uses thereof
WO2007145612A8 (en) Paired end sequencing
WO2012142434A8 (en) Aav mediated ctla-4 gene transfer to treat sjogren's syndrome
AU2015286820A8 (en) Stabilization of poly(A) sequence encoding DNA sequences
WO2008140812A3 (en) Compositions and methods comprising klk3, psca, or folh1 antigen
WO2010120514A3 (en) Antigen-binding proteins comprising recombinant protein scaffolds
WO2010051274A3 (en) Fibronectin type iii domain based scaffold compositions, methods and uses
WO2012088461A3 (en) Linker peptides and polypeptides comprising same
WO2007087178A3 (en) Vaccines and immunotherapeutics using codon optimized il-15 and methods for using the same
WO2008145401A3 (en) Mutated parvovirus structural proteins as vaccines
WO2010093627A3 (en) Fibronectin type iii domain based scaffold compositions, methods and uses
WO2011106766A3 (en) Modified proteins and methods of making and using same
WO2007106476A3 (en) Compositions and methods for enhancing the immunogenicity of antigens
WO2005118813A3 (en) Nucleic acids, polypeptides, methods of expression, and immunogenic compositions associated with sars corona virus spike protein
WO2009137145A3 (en) Transcriptional control in alicyclobacillus acidocaldarius and associated genes, proteins, and methods
EP1989316A4 (en) Method for the production of recombinant virus, dna constructs, recombinant virus and vaccine compositions
WO2008127457A3 (en) Nucleic acids encoding recombinant protein a
WO2012018907A3 (en) Polypeptides for treating and/or limiting influenza infection
WO2007045019A3 (en) Polyoleosins
NZ724196A (en) Uti fusion proteins
WO2009087110A8 (en) Secretable hiv entry inhibitory peptides for therapy of hiv infection
WO2008122817A3 (en) Immunogenic compositions
WO2009009039A3 (en) Compositions containing full-length l1r nucleic acid and endoplasmic reticulum targeting sequence

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980112893.6

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09727698

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2009231559

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 3537/KOLNP/2010

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2011503242

Country of ref document: JP

Ref document number: 2720166

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2009231559

Country of ref document: AU

Date of ref document: 20090406

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20107024734

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2009727698

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12936186

Country of ref document: US